Q3 2023: New strategic focus and improved sales trend
Important events during the third quarter · Net sales increased by 8% (6% adjusted for currency effects) to SEK 156 m (145). · The EBITDA margin amounted to 18% (25) or 20% adjusted for items affecting comparability. · New strategic focus areas and financial targets. · New clinical study in metabolic health shows clear benefits with Probi's bacterial strains, which opens up a new health area. · Third clinical trial of HEAL9™ published, strengthens evidence of improved cognitive performance. Important events after the end of the period · Launch of Probi[®] Sensia, a